Immunovant Stock (NASDAQ:IMVT)

Forecast Ownership Financials Chart

Previous Close

$16.95

52W Range

$12.72 - $34.47

50D Avg

$16.20

200D Avg

$20.97

Market Cap

$2.87B

Avg Vol (3M)

$1.30M

Beta

0.62

Div Yield

IMVT Company Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

362

IPO Date

Jun 21, 2019

Website

IMVT Performance

IMVT Financial Summary

	Mar 25	Mar 24	Mar 23
Revenue	-	-	-
Operating Income	$-438.15M	$-282.71M	$-198.47M
Net Income	$-413.84M	$-259.34M	$-210.96M
EBITDA	-	$-269.98M	$-209.63M
Basic EPS	$-2.73	$-1.88	$-1.71
Diluted EPS	$-2.73	$-1.88	$-1.71

Fiscal year ends in Mar 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 22Jun 09, 22 | 8:00 AM

Q1 22Aug 09, 21 | 8:00 AM

Peer Comparison

Ticker	Company
ROIV	Roivant Sciences Ltd.
KRYS	Krystal Biotech, Inc.
RVMD	Revolution Medicines, Inc.
APLS	Apellis Pharmaceuticals, Inc.
REPL	Replimune Group, Inc.
AKRO	Akero Therapeutics, Inc.
IGMS	IGM Biosciences, Inc.
PCVX	Vaxcyte, Inc.